Patent: 5,928,643
✉ Email this page to a colleague
Summary for Patent: 5,928,643
Title: | Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation |
Abstract: | Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed. |
Inventor(s): | Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA) |
Assignee: | Biogen, Inc. (Cambridge, MA) |
Application Number: | 08/460,132 |
Patent Claims: | see list of patent claims |
Details for Patent 5,928,643
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | 01/30/2003 | ⤷ Try a Trial | 2016-07-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,928,643
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9216622 | ⤷ Try a Trial |
United States of America | 5914111 | ⤷ Try a Trial |
United States of America | 5728677 | ⤷ Try a Trial |
United States of America | 5547853 | ⤷ Try a Trial |
Singapore | 47766 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |